{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT06500676","nct_id":"NCT06500676","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06500676. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":null,"label":"GFH375","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"conditions":["KRAS G12D Mutations","Advanced Solid Tumors"],"enrollment":{"count":407,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"GFH375","type":"DRUG"}],"last_update":"2025-11-20","lead_sponsor":"Genfleet Therapeutics (Shanghai) Inc.","official_title":"An Open-Label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GFH375 in Patients With KRAS G12D Mutant Advanced Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2028-07-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase Ia:The incidence and severity of AEs and SAEs","timeFrame":"24 months"},{"measure":"Phase Ia:The incidence of DLT events","timeFrame":"21 days"},{"measure":"Phase Ib:The incidence and severity of AEs and SAEs","timeFrame":"24 months"},{"measure":"Phase II:Overall response rate (ORR)","timeFrame":"24 months"}],"references":[{"citation":"Ai X, Song Z, Wu L, Zhou A, Cheng D, Zong H, Wu H, Niu Z, Sun Y, Zhu L, Li Z, Deng Y, Yuan Y, Qu X, Zhao H, Du Y, Li Z, Wang Y, Shen H, Zhu H, Zheng C, Wang S, Cui Z, Tai L, Lu S. Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial. Nat Med. 2026 Sep;32(9):3302-3312. doi: 10.1038/s41591-026-04559-4. Epub 2026 Sep 15.","pmid":"42745055","type":"DERIVED"}],"start_date":{"date":"2024-07-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","url":"https://clinicaltrials.gov/study/NCT06500676"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06500676"}